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Abstract
Thisproject tested a two-way model of
communication between lay groups and experts about
genetic medicine in Perth, Western Australia. Focus
group discussion with community groupparticipants
wasfollowed by a communication workshop between
community groupparticipants and experts.
Fourgroups ofconcerns or themes emergedfrom
discussion: clinical considerations; legislative concerns;
research priorities, and ethical and wider
considerations. Community group concerns are not
always met by the actions of "experts". This is, in
part, because ofthe differing life-worlds ofeach
group. However, the communication workshop
showed thepotential oftwo-way communicationfor
both lay and expert members in understanding the
others'viewpoint. Further, the approach developed
here offers onepossible wayfor community groups to
participate in a substantial way inpolicyformulation
processes.
(Journal ofMedical Ethics 1999;25:335-339)
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The application of new gene technologies to
human medicine takes place in the context of
intense public interest, with both positive support
for the prospect of more effective treatment of a
range ofhuman diseases, and fear and apprehen-
sion about a "brave new world" of genetic
engineering. As far as most medical research
scientists and medical practitioners are con-
cerned, these fears are a result of media
sensationalism and a lamentable public ignorance
about the basic science involved, and are best met
by more effective communication of information
about scientific principles and technical proce-
dures. However, as in other areas ofgene technol-
ogy, such as agricultural biotechnology, public
ambivalence cannot be explained simply in terms
of a lack of scientific understanding. Ordinary
people are likely to view scientific developments
more contextually, interpreting them within a
range of broader concerns they may have about
the political and cultural significance of science
and medicine more generally.
In the light ofthis, effective public communica-
tion about developments in genetic medicine
involves not just a one-way transmission ofinfor-
mation from the experts to the public, but rather
a two-way communication in which lay people are
able to articulate their more general "life-world"
concerns to the researchers and medical practi-
tioners.
The creation of more dialogical forms of
communication between experts and lay people
has been attempted through the use of consensus
conferences involving lay panels' 2 as well as focus
groups and "peer conversation" groups.3 These
various communication settings have enabled a
much more open exploration ofoften inarticulate
beliefs and values.4 Consensus conferences ofthe
form developed in Denmark, the Netherlands and
the United Kingdom have given lay people them-
selves the opportunity to set the agenda by
formulating the questions they wish to raise about
a specific topic in their own terms.
In this paper we report on a workshop involving
expert-lay dialogue about developments in genetic
medicine, specifically in relation to gene therapies
for cystic fibrosis (CF). This workshop was the
fourth and final phase of a three-year project on
Public Perceptions of Biotechnology, conducted in
Perth, Western Australia. The first two phases of
this project involved the use ofqualitative one-to-
one and focus-group interviews with representa-
tives of "interested publics" in relation to the
advent of two gene-technology products: the
Flavr-Savr tomato, and the use ofthe growth hor-
mone, pST, for improved pork production. The
third phase involved the use offocus-group inter-
views to investigate the views of a more extensive
range of community groups interested in the
development of gene therapies for the treatment
of cystic fibrosis. Since these interviews provided
the immediate background to the gene-
technology communication workshop and the
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participants, before discussing the workshop, we
shall briefly outline what they involved.
Background
The aim ofthe earlier focus-group interviews was
to explore in a more dialogical or conversational
way the views ofa range of"interested publics" on
developments in genetic medicine. As a focus for
discussion, we chose the development of gene
therapies for cystic fibrosis. After contacting over
one hundred associations in Perth, Western
Australia with interests in community health
issues, we eventually conducted focus-group
discussions with 16 groups, representing a wide
cross-section of disability support groups, com-
munity health groups and "belief" groups with
concerns about medical ethics. At the beginning
of each group discussion, the participants were
provided with two sorts of stimulus and resource
materials. The first was a "scenario" involving a
couple planning to have a baby who were
potentially carriers of the CF gene and who thus
needed to consider a range of options, including
genetic counselling and genetic diagnosis. The
second involved a multimedia "information pack-
age" contained within a HyperCard stack on a
Macintosh PowerBook. The information package
was structured around a range of nine topics or
question areas frequently raised in relation to
genetic medicine. Using text and diagrams
arranged under these topics, the package summa-
rised a range ofinformation, arguments and issues
relevant to the development of gene therapy for
cystic fibrosis. For each group, the information
stack functioned as a resource and a stimulus for
discussion. With the help ofthe group facilitator,
each group was free to choose which of the nine
categories it wished to explore, in what order and
at what speed. The package was reviewed for
accuracy by the local CF support group, a practis-
ing clinical geneticist and a representative of
Genethics, a Melbourne-based, non-government
organisation, which has been publicly critical of
gene technology.
Sixteen focus-group discussions were con-
ducted between 21 September 1996 and 15
March 1997 with a total of95 individuals partici-
pating. The groups ranged in size from three to
nine individuals. The discussions were held on the
campus of Murdoch University. Each discussion
was approximately two hours in duration and was
facilitated by two research staff. The sessions were
tape-recorded and transcribed.
The workshop: aims, method and process
The aim of the gene-technology communication
workshop was to continue the conversations
begun in the separate focus groups, by enabling
representatives from each of the groups to pose
some of the questions raised in their group
discussion to a panel of experts. Although the
model for the workshop was that ofthe consensus
conferences on biotechnology held in Europe and
the UK in recent years, it differed in a number of
ways. Obviously, it was conducted on a much
smaller scale and shorter time-frame. More
importantly, whereas, for example, the consensus
conference on plant biotechnology held in Lon-
don in November 1994 deliberately drew on
members of the general public with no previous
active involvement in the issue, the purpose ofour
workshop was to involve community groups with
an active continuing interest in the issue in
conversation with the experts.
The workshop process involved two meetings
after the completion ofthe series offocus groups.
The first was a meeting (on 20 September 1997)
of representatives from the fourteen groups able
to participate in the workshop. The groups
participating were: Health Network ofWA; Cystic
Fibrosis Association of WA; Birth Issues Group;
SOMA Health Association; Huntington's Disease
Association of WA; Australian Family Associ-
ation; Greenteach; Tourette Syndrome Organis-
ation; Buddhists; Humanist Society of WA;
Cancer Support Association; Haemophilia Foun-
dation; Catholics, and Protestant Christians.This
preliminary meeting provided the lay representa-
tives with an opportunity to meet each other, to
share the issues and concerns raised in their earlier
focus-group discussions and to formulate a series
of questions they wished to raise with a panel of
experts.
The workshop itself was held on 11 October,
1997 at Murdoch University, between twelve of
these participants (representatives of Greenteach
and Tourette Syndrome Organisation were not
present) and a reference panel with expertise in
various aspects ofgenetic medicine, public health
and medical ethics. The seven experts were: a
medical geneticist who had wide experience in
counselling; a director of a bioethics centre; an
anatomist (an expert in human reproduction); a
judge ofthe federal court ofAustralia with a con-
tinuing interest in law and genetics; a state
government technology policy adviser with a par-
ticular interest in biotechnology policy issues; a
medical doctor with expertise in respiratory
medicine (who was conducting research in human
gene therapy), and a senior policy officer in repro-
ductive technology with the Health Department
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Lay questions
The questions raised by the lay participants were
considered in four thematic groups: clinical
considerations; legislative concerns; research pri-
orities, and wider considerations. The specific
questions posed at the first meeting, plus
additional background comment, had been circu-
lated to the expert panel prior to the workshop.
The series ofquestions were as follows:
Theme 1: clinical considerations
1) What are people's rights to privacy with respect to
genetic information?
Do family members, among others, have a right
to know? Can and should insurance companies
have access to genetic information? What is the
right to privacy for research?
Ifyou agree to testing are you obliged to pursue
treatments? What is the "right" to hide a genetic
condition within families (for example, couples,
marriage contracts)? Would stringent divulgence
regulations dissuade people from having a genetic
test?
(2) Is genetic screening inherently discriminatory
and therefore contradictory to the position that all
human beings, including those with genetic disorders,
are equally valued?
(3) How can the social conditions of informed
choice be established aroundgene technology?
What is the role of counselling? Is "consulta-
tion" a better approach/term than "counselling".
Is human sensitivity lacking in counselling? Do
genetic counsellors not take account ofa person's
particular needs or prior knowledge or education?
Do not people need to be empowered to take
responsibility by being well informed, rather than
being instructed what to do by experts? Why are
there no references to support groups in a lot of
cases when a genetic disorder is diagnosed?
Theme 2: legislative concerns
(4) Who will impose regulationlcontrols? Will
regulationslcontrols be voluntary or compulsory?
What happens when there is diagnosis of
late-onset conditions that don't develop? What are
the effects of unnecessary stress from this
"mis-diagnosis", where a probability of a disease
occurring may be interpreted as a certainty? Is
individual choice enough, given the entire social
context choices related to gene technology?
(5) How can we have alegislativeframework which
can keep abreast of scientific developments and
contemporary community values? Should not legisla-
tors stay abreast ofgene technology developments as
well as socialperspectives on the technology?
Theme 3: research priorities
(6) Who will benefit from gene technology given
financial limitations? What does it replace? Who
decides ifgene technology is ofmore social value than
other approaches?
Is too much money/resources spent on gene
technology and not enough on causes (for
example, environmental, nutritional)? Is there
enough research on genetic disorders arising
recently without history ofinheritance (for exam-
ple, environment, nutritional factors, reduced
sperm numbers etc...)?
(7) Is gene technology motivated by private
ownershiplprofit rather than the betterment ofhuman-
ity?
For what percentage ofthe population will gene
technology have benefits and are those finances
going to be diverted from some other part of the
health budget? Is it a cure for present and future
generations? Is there a requirement for three gen-
erational follow-up. Who, if anyone is going to
provide this long term support?
(8) Who paysfor it? Who selects? Who gets it?
Have financial aspects been sufficiently consid-
ered: costs/benefits, for example, smoking and
health costs versus tobacco industry profits and
taxes?
Theme 4: wider considerations
(9) Whatgene intervention is offlimits? Who sets the
end?
What are the limits of testing? Is the infor-
mation balanced? What are the ethics ofscientists
involved in genetic research? What part does eth-
ics play in their training? How are ethics commit-
tees appointed? Are science and technology
running ahead ofethics?
(10) What individual values will be bought to bear
in making gene-technology-related decisions and how
can we ensure that these decisions will be made with
compassionate and balanced motives?
(11) Is the rhetoric ofindividual choice sufficient to
prevent theflourishing ofa new eugenics programme?
(12) Given that gene therapy is already available
and that germ line therapy is being done, why should
we trust scientists to be responsible?
Is a Brave New World imminent? Is there a dan-
ger to human gene diversity? Are there unforeseen
consequences of gene-technology modifications,
as with the introduction of feral animals to the
Australian ecology?
(13) How can we ensure the debate around gene
technology is rational and not dominated by minority
groups trying to impose their views on the wider com-
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Workshop discussion
The responses of the experts and discussions
arising out of these questions are briefly sum-
marised:
Clinical considerations
The initial set of questions led to a discussion of
the principles and procedures of genetic counsel-
ling, particularly with respect to privacy issues.
There were criticisms of a top-down approach to
counselling, with the recommendation that it
should be changed to reflect a more consultative
approach. There was a degree of uncertainty
amongst professional counsellors about the status
of privacy with regard to gene technology. The
current legal status ofresponsibilities ofdisclosure
with regard to the insurance industry were
clarified. The use oftesting for the "elimination"
of people was proposed as discriminatory; how-
ever, the legal issues about discrimination against
living people and the moral issue about the status
ofthe fetus were seen as different. It was also sug-
gested that the practice of preimplantation
diagnosis was required by the Hippocratic princi-
ple of "doing-less-harm" to which medical
doctors are morally bound (ie transferring a
defective embryo causes harm).
Legislative concerns
Who should, rather than who will regulate gene
technology was raised as an issue. Regulations
currently in place for gene therapy trials are
already stringent. Another issue was: How could
legislation keep abreast of research and commu-
nity values? There is a widespread overestimation
of the possibilities for, and positive impacts of,
genetic screening, according to some members of
the reference panel.
Researchpriorities
The conviction was expressed that environmental/
nutritional factors cause many of our contempo-
rary genetic disorders. The issue of how the
empowerment of community members - through
provision ofbasic information abouthealthy living
and self-diagnosis (such as SOMA produces) -
might undercut dependence upon, and thus the
economic profitability of, pharmaceutical prod-
ucts, was raised. Biotechnology policy was seen as
being "community driven"; one participant de-
scribed her experience ofthe influence ofdoctors
in shaping people's opinions. There was insuffi-
cient community discussion about what people
wanted from gene technology, or, more generally,
what the community priorities for health re-
sources were.
Wider considerations
Clinicians are motivated by the concern to allevi-
ate the suffering of patients (nothing would
necessarily be off limits if it contributed to this
aim). The claim was made that the power ofgene
technology pales into insignificance besides the
power of nature; this argument has, of course,
been central to many discourses on technological
progress. It was suggested that gene technology
would just not be able to produce designer babies
and the like, and thus community concerns ofthis
kind were simply unfounded. Exaggerated claims
are made about gene technology; it was empha-
sised how fora ofthis kind reveal that we - experts
and lay people alike - are all ordinary people
struggling with difficult questions and contingent
responsibilities. This question produced wide dis-
cussion about the need for legal and professional
guidelines for making balanced decisions, but
none of the panellists took up the moderator's
suggestion to discuss the personal aspect ofdevel-
oping a balanced stance. The final question from
the community participants about the undue
influence ofminority groups, produced discussion
about the need for clear legal, regulatory frame-
works.
Conclusions
In this briefreport, two broad conclusions may be
drawn from the workshop.
The first concerns the nature and range of
questions raised. The set ofquestions arose out of
a comparatively extended process ofreflection by
groups of lay people and thus represent well-
considered concerns on the part ofpeople with an
active, continuing interest in the development of
genetic medicine. An obvious characteristic ofthis
set of questions is the emphasis on the broader,
more contextual, social and ethical ramifications
of the new genetics. Clearly, it is these kinds of
questions which should be central to the continu-
ing public debate about the new genetics.
The second concerns the potential of this kind
of workshop as a tool for broader public debate
and public policy development. First, there is a
positive benefit in identifying the range of
interested publics concerned with an issue and
proactively involving them in a process of policy
discussion. This more targeted approach may be
more useful than trying to educate or inform "the
general public". The kind of groups involved in
the workshop bring to the discussion valuable
background knowledge and experience which
helps to contextualise effectively the more techni-
cal discussions of medical experts. Also they are
potentially "vitally interested allies" for the scien-
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better forms ofcommunication with the networks
of people involved in disability support groups,
alternative health activities and religious commu-
nities. Second, there is the value of the kind of
conversation which this particular process gener-
ates. In contrast to more conventional public
inquiries in which a discussion paper establishes
the terms and topics for discussion, this process
gives an opportunity to interested publics to shape
the discussion in their own terms. Third, this kind
of workshop provides a space for discussion
between the medical profession and patients'
groups that is more public than the clinical
context and thus allows the policy concerns of
these groups to be heard.
It is recognised that by itself, this sort ofwork-
shop is likely to have little continuing impact.
However, we believe that it does have the potential
to be used as a more proactive tool in the attempt
to establish more effective communication be-
tween the scientific community and the medical
profession on the one hand and a wider set of
interested publics on the other. It could also be
used in a process ofpolicy formulation, for exam-
ple, in the review of the Western Australian
Reproductive Technology Act, which has been
taking place over the past year or so.
In our view, the capacity oflay people with sig-
nificant interests in gene technology issues to
engage in community consultations is a particu-
larly valuable resource for continuing policy
development. We believe that the use of such
processes to facilitate lay deliberation should be
more actively developed for the purposes ofboth
communicating new developments in genetics
and involving lay publics in policy development.
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